June 15, 2022
The immune system’s ability to detect nascent tumors requires the presentation of protein fragment (peptide) antigens that it can recognize. Due to limitations in how samples are collected and studied, researchers have difficulty identifying peptide presentation patterns specific to cancer. However, an ongoing Jacks Lab/White Lab collaboration, originally begun as a hallway conversation between colleagues, shows the power of combining engineered mouse models with mass spectrometry to better profile the collection of immunopeptides on the surface of cancer cells. The researchers' latest paper, published in Nature, reveals new tumor antigens potentially useful for immunotherapies and understanding of immune response.